A detailed history of Byrne Asset Management LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Byrne Asset Management LLC holds 250 shares of MYGN stock, worth $3,097. This represents 0.01% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$3,097
Previous $5,000 20.0%
% of portfolio
0.01%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

SELL
$13.91 - $21.32 $3,477 - $5,330
-250 Reduced 50.0%
250 $4,000
Q2 2023

Jul 21, 2023

BUY
$17.56 - $23.76 $8,780 - $11,880
500 New
500 $11,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $999M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Byrne Asset Management LLC Portfolio

Follow Byrne Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.